| Customization: | Available |
|---|---|
| CAS No.: | 57808-66-9 |
| Formula: | C29h27f3n6o |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Ponatinib |
| Apperance | Light yellow powder |
| CAS | 943319-70-8 |
| MF | C29h27f3n6o |
| MW | 532.56 |
Overcoming Resistance
Ponatinib's unique structure allows it to bypass common resistance mechanisms, including mutations that disrupt drug binding (e.g., T315I, F317L). Its high potency (IC50 of 0.37 nM for BCR-ABL1) ensures suppression of leukemic cell proliferation even at low concentrations.
Safety and Tolerability
While highly effective, Ponatinib carries a black box warning for vascular occlusion (arterial and venous thrombosis), heart failure, and hepatotoxicity. In clinical trials, 20-25% of patients experienced serious cardiovascular events, necessitating careful risk-benefit assessment. Common adverse effects include hypertension (30%), rash (25%), and pancreatitis (5%). Dose adjustments or discontinuation may be required for severe toxicity.
Role in Precision Medicine
Ponatinib exemplifies targeted cancer therapy, with efficacy guided by genetic testing for BCR-ABL1 mutations. It is reserved for patients with confirmed T315I mutations or those failing multiple TKIs.
){kind=link}